Very little pharmacokinetic data for critically ill paediatric patients currently exists. It is highly likely that the same pharmacokinetic changes observed in critically ill adults will also occur in children leading to subtherapeutic concentrations that risk treatment failure and the emergence of resistant pathogens.

To date, little data is available to characterise antimicrobial pharmacokinetics in these patients, particularly for antimicrobials recommended by Australian guidelines piperacillin/tazobactam, cefotaxime and vancomycin.

Project members

Professor Jeffrey Lipman

Chief Investigator